FindTrial
Sign In

Estimation of cost value for health care professionals based on the convenience of anti-influenza agent baloxavir marboxil

Estimation of cost value for health care professionals based on the convenience of anti-influenza agent baloxavir marboxil - Estimation of cost value for health care professionals based on the convenience of anti-influenza agent baloxavir marboxil

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000042606
Enrollment
2750
Registered
2020-12-01
Start date
2020-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

influenza

Interventions

None listed

Sponsors

Shionogi & Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Physicians, pharmacists, or care workers.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

MeasureTime frame
Length of time and frequency of drug administration instruction/assistance.—

Secondary

MeasureTime frame
Whether to feel worried about infection or not and willing to pay to avoid infection risk when doing drug administration instruction/assistance.—

Countries

Japan

Contacts

Public ContactKenji Kurazono

Shionogi & Co., Ltd. Medical Affairs Dept.

kenji.kurazono@shionogi.co.jp06-6485-5201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026